On March 29, 2023 ProQR will host a virtual R&D event to showcase its proprietary Axiomer RNA-editing technology platform. ProQR will also announce initial pipeline targets for internal development.
Daniel A. de Boer, Founder and CEO, will participate in the ADAR Editing Panel at the Chardan 7th Annual Genetic Medicines Conference. A recording of the session is available below.
ProQR management will host an investor conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the recently announced partnership with Lilly.
… machinery. Axiomer® RNA editing technology harnesses ADAR(Adenosine Deaminase Acting on RNA), which is machinery … with wet-lab scientists, technicians, project leads. Skills and competencies that are required for making …
… machinery. Axiomer® RNA editing technology harnesses ADAR(Adenosine Deaminase Acting on RNA), which is machinery … designing and implementing a new product planning process Leads new product planning, positioning, and pre-launch …
… machinery. Axiomer® RNA editing technology harnesses ADAR(Adenosine Deaminase Acting on RNA), which is machinery … Leiden, NL (on-site) The Senior Clinical Scientist will lead the scientific and operational elements of the Clinical …